Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 9, 2013

DARPA Awards Techulon $1.9M to Develop ‘Superbug’ Drug

  • The Defense Advanced Research Projects Agency (DARPA) has awarded Techulon $1.9 million to advances its therapeutic program for multidrug-resistant bacteria, so-called superbugs, through a Phase II contract, the nucleic acid therapeutics development firm said.

    Through this award, Techulon aims to advance the development of a nanotherapeutic agent through critical milestones toward clinical trials, the company added.

    “We are pleased to extend our work in Rapidly Adaptable Therapeutics with DARPA. This program will lead to better therapies for wounded soldiers and civilians affected by multi-drug resistant hospital-acquired infections,” Techulon CSO Joshua Bryson, Ph.D., said in a statement.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »